Understanding and targeting the DNA replication stress in cancer cells
了解并针对癌细胞中的 DNA 复制压力
基本信息
- 批准号:10813321
- 负责人:
- 金额:$ 94.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-24 至 2028-06-30
- 项目状态:未结题
- 来源:
- 关键词:ATR checkpointAffectCellsDNA RepairDNA biosynthesisEventGenetic TranscriptionGenomeGenomic InstabilityHumanMalignant NeoplasmsModelingMolecularOncogenicPathway interactionsPoly(ADP-ribose) Polymerase InhibitorPopulationRNARegulationSignal TransductionSourceStressTherapeuticTranscriptWorkanticancer researchbiological adaptation to stresscancer cellcancer genomecancer therapyinterestmutantrepairedreplication stresssuccesstargeted treatmenttumortumor microenvironment
项目摘要
Project Summary
DNA replication problems collectively known as replication stress are a major sources of genomic instability in
cancer cells and also a vulnerability of cancer that can be targeted therapeutically. The recent success of PARP
inhibitors in the treatment of BRCA mutant tumors provided an exciting example of targeting cancer cells by
exploiting replication stress. However, our current understanding of the replication stress in cancer cells is still
very limited. Although we know that many different oncogenic events in cancer cells can cause replication
problems, we still don't fully understand whether these oncogenic events affect DNA replication in similar or
distinct ways. Furthermore, we also know little about how DNA replication is altered by different oncogenic
events, and whether altered replication can give rise to distinct cellular vulnerabilities. Understanding the basic
molecular features of replication stress, the major causes of replication stress in cancer cells, and the different
vulnerabilities resulting from altered replication will greatly enhance our ability to detect and exploit replication
stress in cancer therapy.
I have a longstanding interest in understanding the replication stress response in human cells. In particular, my
lab has extensively studied the functions and regulation of the ATR checkpoint pathway, the master regulator of
replication stress response in human cells. Our work has contributed significantly to the current models of stress
sensing and signaling during DNA replication. From recent studies by us and others, it has become gradually
clear that different oncogenic events in cancer cells can generate distinct problems in DNA replication.
Furthermore, RNA transcripts, the products of transcription, have both positive and negative impacts on DNA
replication and repair. Our studies also revealed that replication stress not only exerts cell autonomous effects
on the genome, but also cell non-autonomous effects in cell populations. Based on these new findings, we
propose to systematically define and characterize different types of replication stress in cancer cells, understand
how RNA affects replication and repair in the genome, and explore the cell non-autonomous effects of replication
stress in tumor microenvironments and cancer therapy. These studies may provide us a much more
comprehensive understanding of the molecular underpinnings of replication stress in cancer cells, their impacts
on the genome of cancer cells and cell populations in tumor microenvironments, and the cancer cell-specific
vulnerabilities that they give rise to. The new concepts and findings from these studies could have transformative
impacts on the research of cancer and cancer therapy.
项目概要
DNA 复制问题统称为复制应激,是基因组不稳定的主要来源。
癌细胞以及可以进行靶向治疗的癌症的脆弱性。 PARP 最近的成功
抑制剂在治疗 BRCA 突变肿瘤中提供了一个令人兴奋的靶向癌细胞的例子
利用复制压力。然而,我们目前对癌细胞复制应激的理解仍然不明确。
非常有限。尽管我们知道癌细胞中许多不同的致癌事件都会导致复制
问题,我们仍然不完全了解这些致癌事件是否会影响类似或类似的 DNA 复制
不同的方式。此外,我们对不同致癌基因如何改变 DNA 复制也知之甚少。
事件,以及复制的改变是否会导致不同的细胞脆弱性。了解基本知识
复制应激的分子特征、癌细胞复制应激的主要原因以及不同的复制应激
复制更改导致的漏洞将大大增强我们检测和利用复制的能力
癌症治疗中的压力。
我长期以来对了解人类细胞的复制应激反应很感兴趣。特别是我的
实验室广泛研究了 ATR 检查点通路的功能和调节,ATR 检查点通路是
人类细胞的复制应激反应。我们的工作对当前的压力模型做出了重大贡献
DNA 复制过程中的传感和信号传导。从我们和其他人最近的研究来看,它已经逐渐变得
很明显,癌细胞中不同的致癌事件会在 DNA 复制中产生不同的问题。
此外,RNA转录物(转录产物)对DNA既有积极的影响,也有消极的影响
复制和修复。我们的研究还表明,复制压力不仅会产生细胞自主效应
对基因组的影响,而且对细胞群体的细胞非自主效应也有影响。基于这些新发现,我们
提议系统地定义和表征癌细胞中不同类型的复制应激,了解
RNA如何影响基因组的复制和修复,并探索复制的细胞非自主效应
肿瘤微环境和癌症治疗中的压力。这些研究可能为我们提供更多信息
全面了解癌细胞复制应激的分子基础及其影响
肿瘤微环境中癌细胞和细胞群的基因组以及癌细胞特异性
它们引起的漏洞。这些研究的新概念和发现可能具有变革性
对癌症和癌症治疗研究的影响。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
TERRA and RAD51AP1 promote alternative lengthening of telomeres through an R- to D-loop switch.
TERRA 和 RAD51AP1 通过 R 环至 D 环开关促进端粒的选择性延长。
- DOI:
- 发表时间:2022-11-03
- 期刊:
- 影响因子:16
- 作者:Yadav, Tribhuwan;Zhang, Jia;Ouyang, Jian;Leung, Wendy;Simoneau, Antoine;Zou, Lee
- 通讯作者:Zou, Lee
DNA repair defects in cancer and therapeutic opportunities.
癌症中的 DNA 修复缺陷和治疗机会。
- DOI:
- 发表时间:2022-03-01
- 期刊:
- 影响因子:10.5
- 作者:Hopkins, Jessica L;Lan, Li;Zou, Lee
- 通讯作者:Zou, Lee
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lee Zou其他文献
Lee Zou的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lee Zou', 18)}}的其他基金
Understanding and targeting the DNA replication stress in cancer cells
了解并针对癌细胞中的 DNA 复制压力
- 批准号:
10457394 - 财政年份:2021
- 资助金额:
$ 94.63万 - 项目类别:
Understanding and targeting the DNA replication stress in cancer cells
了解并针对癌细胞中的 DNA 复制压力
- 批准号:
10299702 - 财政年份:2021
- 资助金额:
$ 94.63万 - 项目类别:
Impacts of APOBECs on DNA replication, ATR checkpoint, and cancer therapy
APOBEC 对 DNA 复制、ATR 检查点和癌症治疗的影响
- 批准号:
10152561 - 财政年份:2018
- 资助金额:
$ 94.63万 - 项目类别:
Impacts of APOBECs on DNA replication, ATR checkpoint, and cancer therapy
APOBEC 对 DNA 复制、ATR 检查点和癌症治疗的影响
- 批准号:
9920694 - 财政年份:2018
- 资助金额:
$ 94.63万 - 项目类别:
Implications of the ATR Checkpoint Kinase in Radiation and Targeted Therapies
ATR 检查点激酶在放射和靶向治疗中的意义
- 批准号:
9973670 - 财政年份:2015
- 资助金额:
$ 94.63万 - 项目类别:
Implications of the ATR Checkpoint Kinase in Radiation and Targeted Therapies
ATR 检查点激酶在放射和靶向治疗中的意义
- 批准号:
9306691 - 财政年份:2015
- 资助金额:
$ 94.63万 - 项目类别:
Regulation of the ATR Checkpoint Kinase by DNA Damage
DNA 损伤对 ATR 检查点激酶的调节
- 批准号:
8720012 - 财政年份:2006
- 资助金额:
$ 94.63万 - 项目类别:
Regulation of the ATR Checkpoint Kinase by DNA Damage
DNA 损伤对 ATR 检查点激酶的调节
- 批准号:
8523909 - 财政年份:2006
- 资助金额:
$ 94.63万 - 项目类别:
Regulation of the ATR Checkpoint Kinase by DNA Damage
DNA 损伤对 ATR 检查点激酶的调节
- 批准号:
9340218 - 财政年份:2006
- 资助金额:
$ 94.63万 - 项目类别:
Regulation of the ATR Checkpoint Kinase by DNA Damage
DNA 损伤对 ATR 检查点激酶的调节
- 批准号:
8321983 - 财政年份:2006
- 资助金额:
$ 94.63万 - 项目类别:
相似国自然基金
高尿酸调控TXNIP驱动糖代谢重编程影响巨噬细胞功能
- 批准号:82370895
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
TRAF6/Caveolin-1/p62功能轴介导高自噬水平CAFs与肿瘤细胞形成“代谢耦连”关系影响胰腺癌侵袭转移的机制研究
- 批准号:82372964
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
探究3D微环境挤压力对微核介导的肿瘤细胞内炎化的影响及力学作用机制
- 批准号:12302410
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
BeAn 58058病毒影响cofilin 1功能介导重型再生障碍性贫血患者髓样树突状细胞激活及其机制的研究
- 批准号:82300239
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
小胶质细胞特异罕见易感突变介导相分离影响阿尔茨海默病发病风险的机制
- 批准号:82371438
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Regulation of transcription termination by checkpoint kinases Mec1p and Rad53p
检查点激酶 Mec1p 和 Rad53p 对转录终止的调节
- 批准号:
10729762 - 财政年份:2023
- 资助金额:
$ 94.63万 - 项目类别:
Alpha particles combined with ATR inhibition to activate the immune system: mechanisms and pre-clinical translation
Alpha 粒子结合 ATR 抑制激活免疫系统:机制和临床前转化
- 批准号:
10636348 - 财政年份:2023
- 资助金额:
$ 94.63万 - 项目类别:
Understanding and targeting the DNA replication stress in cancer cells
了解并针对癌细胞中的 DNA 复制压力
- 批准号:
10457394 - 财政年份:2021
- 资助金额:
$ 94.63万 - 项目类别:
Understanding and targeting the DNA replication stress in cancer cells
了解并针对癌细胞中的 DNA 复制压力
- 批准号:
10299702 - 财政年份:2021
- 资助金额:
$ 94.63万 - 项目类别:
Targeting cholesterol metabolism and replication stress response in cancer therapy
癌症治疗中针对胆固醇代谢和复制应激反应
- 批准号:
10328961 - 财政年份:2021
- 资助金额:
$ 94.63万 - 项目类别: